The function of NAT10-driven N4-acetylcytidine modification in cancer: novel insights and potential therapeutic targets
Yi Wang, Sheng Wang, Maoyun Liu, Cheng Zhang, Zuotian Huang, Fengsheng Dai, Dewei Li, Hui Li · 2025
Read The function of NAT10-driven N4-acetylcytidine modification in cancer: novel insights and potential therapeutic targets by Yi Wang, Sheng Wang, Maoyun Liu, Cheng Zhang, Zuotian Huang, Fengsheng Dai, Dewei Li, Hui Li (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12664269.txt.
Description
Yi Wang and co-authors review how one RNA-editing enzyme drives cancer through a chemical mark on RNA letters. Their 2025 review covers the mark called ac4C and its sole known writer enzyme, NAT10. The mark changes RNA shape, which shifts how stable messages are and how fast they are read into protein.
Across tumors, the enzyme can act as a growth driver or, in some settings, as a brake. That split role makes it a candidate outlook marker and drug target. The review links the mark to key signaling paths and to the immune setting around tumors. Hurdles for clinic use remain wide, the authors note. They aim the survey at guiding basic work and care translation alike.
Catalog record
| CREATOR | Yi Wang, Sheng Wang, Maoyun Liu, Cheng Zhang, Zuotian Huang, Fengsheng Dai, Dewei Li, Hui Li |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |